Further research should explore the combined effects of CP-673451 with other tyrosine kinase inhibitors, such as EGFR, FGFR, and VEGFR inhibitors, or chemotherapeutic agents to enhance the effectiveness of CCA treatments. Here, EGFR is linked to cholangiocarcinoma.